Relmada Therapeutics Halts Phase III Studies RELIANCE II and RELIGHT

Brief Summary

Relmada Therapeutics has decided to halt the phase III studies RELIANCE II and RELIGHT for their drug candidate REL-1017 and will explore strategic alternatives while continuing the phase I study of REL-P11 for metabolic diseases.

Impact of The News

The event primarily affects Relmada Therapeutics at the company and product level.

Impact Transmission Path

1. Direct Impact on Relmada Therapeutics:

• The decision to halt the RELIANCE II and RELIGHT studies indicates setbacks in the development of REL-1017, which was under investigation as a treatment adjunct for major depressive disorder (MDD) Benzinga+ 2. This could lead to potential financial and reputational impacts as these trials were significant for their product pipeline.
• The company’s decision to continue with REL-P11’s phase I trials suggests a strategic pivot towards focusing on metabolic disease treatments, possibly reallocating resources and attention from the discontinued studies.

2. Implications for Investors and the Market:

• Investors might view the halting of late-stage trials as a negative signal due to potential delays in bringing new products to market, affecting stock prices and market perception.
• The exploration of strategic alternatives might introduce volatility as investors speculate on possible mergers, acquisitions, or partnerships.

3. Industry-Level Effects:

• Competitors in the MDD treatment space may experience indirect benefits due to reduced competition from Relmada’s REL-1017, potentially strengthening their market positions.
• The shift in focus to metabolic diseases could influence industry dynamics, impacting competitors and partners in this therapeutic area.

Overall, this event underscores challenges in drug development and highlights the strategic shifts companies undertake in response to clinical trial outcomes.